Blood levels of a collagen fragment (procollagen III peptide) closely tracked the severity of liver scarring in schistosomiasis patients, offering a non-invasive alternative to biopsy.
High correlationSerum procollagen type III peptide levels closely matched the histological degree of liver fibrosis, validating a blood-based alternative to invasive liver biopsy
What the researchers found
Serum levels of the N-terminal procollagen type III peptide (PIIINP) showed a high correlation with the degree of liver fibrosis in patients with schistosomiasis. This peptide biomarker tracked with histopathological findings from liver biopsies, suggesting it could serve as a non-invasive marker to monitor the dynamic process of liver scarring — something a one-time biopsy cannot capture.
Why it matters
Liver biopsy is painful, invasive, and only provides a snapshot of damage at one moment. A blood-based peptide biomarker that reflects ongoing fibrosis activity could allow doctors to track disease progression over time without repeated biopsies. This early study helped establish PIIINP as a clinically useful marker, a concept that has since expanded to many liver diseases beyond schistosomiasis.
The numbers in context
High correlation between serum PIIINP and histological fibrosis grade · Liver function tests correlated with histopathological diagnosis
How the study worked
Researchers measured serum concentrations of procollagen type III peptide and standard liver function tests in patients with schistosomiasis mansoni. These results were compared against histopathological diagnosis from liver biopsies to determine how well the blood marker correlated with the actual degree of liver fibrosis.
Who was studied
Adult patients with schistosomiasis mansoni and varying degrees of liver fibrosis
What this study cannot tell us
The abstract provides limited quantitative data — no specific correlation coefficients, sample sizes, or sensitivity/specificity values are reported. The study focused exclusively on schistosomal liver fibrosis, so generalizability to other causes of liver fibrosis is not established. Being from 1987, the assay technology for measuring PIIINP has since improved significantly.
How to read the evidence
This is an observational clinical study with histopathological confirmation. While it demonstrates a clear correlation, the abstract lacks specific statistical metrics. The single-disease focus and older methodology are limitations, though the core finding has been extensively validated by subsequent research.
When this study was published
Published in 1987, this is a foundational early study in peptide biomarker research. While the assay technology has improved dramatically since then, the core concept — using PIIINP to track liver fibrosis — remains clinically relevant and is now part of validated diagnostic panels.
The bigger picture
This 1987 study was part of the early wave of research establishing peptide-based biomarkers for liver disease. PIIINP has since become one of the most widely validated non-invasive fibrosis markers and is now included in composite scores like the Enhanced Liver Fibrosis (ELF) test used clinically for conditions ranging from hepatitis to NAFLD/MASH. The concept of using collagen fragments as disease biomarkers has expanded far beyond the liver.
Questions still open
- How does PIIINP compare to modern non-invasive fibrosis markers like FibroScan or the ELF score?
- Can serial PIIINP measurements predict which patients will progress to cirrhosis versus stabilize?
- Is this biomarker useful for monitoring treatment response in patients receiving anti-fibrotic therapies?
Common questions
What is procollagen type III peptide and why does it appear in blood during liver disease?
Is this blood test used today?
Read the original research
Serum concentration of N-terminal procollagen peptide of collagen type III in schistosomal liver fibrosis.
Experimental and molecular pathology, 46(3), 383-90
Citation
el-Mohandes, M; Hassanein, H; el-Badrawy, N; Voss, B; Gerlach, U. (1987). Serum concentration of N-terminal procollagen peptide of collagen type III in schistosomal liver fibrosis.. Experimental and molecular pathology, 46(3), 383-90.